Results 111 to 120 of about 231,349 (305)
, 2018 Danyang Sun,* Junxun Ma,* Jinliang Wang, Fan Zhang, Lijie Wang, Sujie Zhang, Guangying Chen, Xiaoyan Li, Wushuang Du, Pengfei Cui, Yi Hu Department of Oncology, Chinese PLA General Hospital, Beijing, China *These authors contributed equally to this ...
Zhang F +10 more
core
Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors
Over the past few years, immune checkpoint inhibitors resulted in magnificent and durable successes in treating cancer; however, only a minority of patients respond favorably to the treatment due to a broad-spectrum of tumor-intrinsic and tumor-extrinsic
Elkord, Eyad +2 more
core +1 more source
Biomarkers associated with checkpoint inhibitors
Annals of Oncology, 2016 Checkpoint inhibitors (CPI), namely anti-CTLA4 and anti-PD1/PD-L1 antibodies, demonstrated efficacy across multiple types of cancer. However, only subgroups of patients respond to these therapies. Additionally, CPI can induce severe immune-related adverse events (irAE).
Manson, G. +4 more
openaire +3 more sources
The Impact of Immune Checkpoint Inhibitors on Fertility Preservation and Pregnancy Outcomes
Journal of Education, Health and SportImmune checkpoint inhibitors have revolutionized cancer treatment by enhancing anti-tumor immune responses. However, their impact on fertility is an emerging concern, particularly among young patients, including children.
Agata Prokopiuk +9 more
doaj +1 more source
PARP inhibitors induce a senescence phenotype in non‐small cell lung carcinoma cell lines
FEBS Open Bio, EarlyView.Talazoparib is the most potent inducer of senescence among different PARP1 inhibitors in human NSCLC cells. In the absence of PARP, no senescence phenotype was observed, demonstrating that PARP1 is necessary for the induction of senescence by this inhibitor.
Camille Huart +7 more
wiley +1 more source
FEBS Open Bio, EarlyView.We first identified functional murine mitochondrial N‐formyl peptides (MT‐FPs) and investigated their effects on the in vitro myeloid‐derived suppressor cell (MDSC) generation from bone marrow cells. We demonstrated that MT‐FPs acted directly on bone marrow cells to promote MDSC generation and modulated the polymorphonuclear (PMN)‐MDSC/monocyte (M ...
Miyako Ozawa +2 more
wiley +1 more source
Resistance mechanisms to immune checkpoint inhibitors: updated insights
The last decade has witnessed unprecedented succusses with the use of immune checkpoint inhibitors in treating cancer. Nevertheless, the proportion of patients who respond favorably to the treatment remained rather modest, partially due to treatment ...
Elkord, Eyad +5 more
core +1 more source
Structural basis for the activity and specificity of the immune checkpoint inhibitor lirilumab
Scientific ReportsThe clinical success of immune checkpoint inhibitors has underscored the key role of the immune system in controlling cancer. Current FDA-approved immune checkpoint inhibitors target the regulatory receptor pathways of cytotoxic T-cells to enhance their ...
Nicholas Lorig-Roach +2 more
doaj +1 more source
Development of human monoclonal antibodies against TARM1 by yeast display
FEBS Open Bio, EarlyView.Human monoclonal antibodies against TARM1 are generated by yeast display‐guided selection. These antibodies bind to soluble and cell‐surface forms of TARM1. Also, these antibodies exhibit agonistic activity in the NFAT‐GFP reporter assay, indicating that TARM1 signaling can be functionally modulated by antibodies and suggesting TARM1 as a potential ...
Rikio Yabe +5 more
wiley +1 more source
FEBS Open Bio, EarlyView.Pharmacological inhibition of PERK in a DEN‐induced mouse model of liver cancer does not reduce tumor burden but alters cellular stress signaling. Despite blocking PERK activity, downstream stress responses, including CHOP expression, remain active, suggesting compensatory mechanisms within the unfolded protein response that may influence tumor ...
Ada Lerma‐Clavero +5 more
wiley +1 more source